Search research articles
Contact Us
Filters
Showing results (81-90 of 165) with videos related to
Page
of 17
Sort By:
Blood
|
September 13, 2003
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Rowena D Faulkner, Charles Craddock, Jennifer L Byrne, et al.
British Journal of Haematology
|
December 29, 2015
Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord
John A Snowden, Robert Danby, Annalisa Ruggeri, et al.
Journal of Hematology & Oncology
|
August 5, 2016
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party
Marie T Rubio, Bipin N Savani, Myriam Labopin, et al.
Transplantation
|
May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Olle Ringdén, Myriam Labopin, Martin Solders, et al.
American Journal of Hematology
|
January 3, 2022
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation
Arnon Nagler, Myriam Labopin, Charles Craddock, et al.
British Journal of Haematology
|
March 9, 2011
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Bronwen E Shaw, Jane F Apperley, Nigel H Russell, et al.
Blood
|
August 12, 2004
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
Emma Morris, Kirsty Thomson, Charles Craddock, et al.
BMC Cancer
|
November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
Richard Dillon, Shanna Maycock, Aimee Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 24, 2009
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition
Sarah Nicholls, Karen P Piper, Fiyaz Mohammed, et al.
British Journal of Haematology
|
November 24, 2018
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies
Charlotte K Brierley, Francesca M Jones, Katharine Hanlon, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 165) with videos related to
Sort By:
Page
of 17
Blood
|
September 13, 2003
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Rowena D Faulkner, Charles Craddock, Jennifer L Byrne, et al.
British Journal of Haematology
|
December 29, 2015
Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord
John A Snowden, Robert Danby, Annalisa Ruggeri, et al.
Journal of Hematology & Oncology
|
August 5, 2016
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party
Marie T Rubio, Bipin N Savani, Myriam Labopin, et al.
Transplantation
|
May 7, 2014
Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Olle Ringdén, Myriam Labopin, Martin Solders, et al.
American Journal of Hematology
|
January 3, 2022
Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation
Arnon Nagler, Myriam Labopin, Charles Craddock, et al.
British Journal of Haematology
|
March 9, 2011
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Bronwen E Shaw, Jane F Apperley, Nigel H Russell, et al.
Blood
|
August 12, 2004
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
Emma Morris, Kirsty Thomson, Charles Craddock, et al.
BMC Cancer
|
November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
Richard Dillon, Shanna Maycock, Aimee Jackson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 24, 2009
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition
Sarah Nicholls, Karen P Piper, Fiyaz Mohammed, et al.
British Journal of Haematology
|
November 24, 2018
Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies
Charlotte K Brierley, Francesca M Jones, Katharine Hanlon, et al.
Page
of 17